Monte Carlo study of LDR seed dosimetry with an application in a clinical brachytherapy breast implant.

A Monte Carlo (MC) study was carried out to evaluate the effects of the interseed attenuation and the tissue composition for two models of 125I low dose rate (LDR) brachytherapy seeds (Medi-Physics 6711, IBt InterSource) in a permanent breast implant. The effect of the tissue composition was investigated because the breast localization presents heterogeneities such as glandular and adipose tissue surrounded by air, lungs, and ribs. The absolute MC dose calculations were benchmarked by comparison to the absolute dose obtained from experimental results. Before modeling a clinical case of an implant in heterogeneous breast, the effects of the tissue composition and the interseed attenuation were studied in homogeneous phantoms. To investigate the tissue composition effect, the dose along the transverse axis of the two seed models were calculated and compared in different materials. For each seed model, three seeds sharing the same transverse axis were simulated to evaluate the interseed effect in water as a function of the distance from the seed. A clinical study of a permanent breast 125I implant for a single patient was carried out using four dose calculation techniques: (1) A TG-43 based calculation, (2) a full MC simulation with realistic tissues and seed models, (3) a MC simulation in water and modeled seeds, and (4) a MC simulation without modeling the seed geometry but with realistic tissues. In the latter, a phase space file corresponding to the particles emitted from the external surface of the seed is used at each seed location. The results were compared by calculating the relevant clinical metrics V85, V100, and V200 for this kind of treatment in the target. D90 and D50 were also determined to evaluate the differences in dose and compare the results to the studies published for permanent prostate seed implants in literature. The experimental results are in agreement with the MC absolute doses (within 5% for EBT Gafchromic film and within 7% for TLD-100). Important differences between the dose along the transverse axis of the seed in water and in adipose tissue are obtained (10% at 3.5 cm). The comparisons between the full MC and the TG-43 calculations show that there are no significant differences for V85 and V100. For V200, 8.4% difference is found coming mainly from the tissue composition effect. Larger differences (about 10.5% for the model 6711 seed and about 13% for the InterSource125) are determined for D90 and D50. These differences depend on the composition of the breast tissue modeled in the simulation. A variation in percentage by mass of the mammary gland and adipose tissue can cause important differences in the clinical dose metrics V200, D90, and D50. Even if the authors can conclude that clinically, the differences in V85, V100, and V200 are acceptable in comparison to the large variation in dose in the treated volume, this work demonstrates that the development of a MC treatment planning system for LDR brachytherapy will improve the dose determination in the treated region and consequently the dose-outcome relationship, especially for the skin toxicity.

[1]  J. Williamson,et al.  Update of AAPM Task Group No. 43 Report: A revised AAPM protocol for brachytherapy dose calculations. , 2004 .

[2]  J. S. Laughlin,et al.  Absorbed radiation dose in mammography. , 1979, Radiology.

[3]  J J DeMarco,et al.  CT-based dosimetry calculations for 125I prostate implants. , 1999, International journal of radiation oncology, biology, physics.

[4]  D E Raeside,et al.  The accuracy of single-seed dose superposition for I-125 implants. , 1989, Medical physics.

[5]  Jean-François Carrier,et al.  Impact of interseed attenuation and tissue composition for permanent prostate implants. , 2006, Medical physics.

[6]  R. Nath,et al.  A comparison of solid phantoms with water for dosimetry of 125I brachytherapy sources. , 1988, Medical physics.

[7]  R. Nath,et al.  Interseed effects on dose for 125I brachytherapy implants. , 1992, Medical physics.

[8]  L. Dewerd,et al.  Brachytherapy dosimetry of 125I and 103Pd sources using an updated cross section library for the MCNP Monte Carlo transport code. , 2003, Medical physics.

[9]  Frank Verhaegen,et al.  A Monte Carlo study on the effect of seed design on the interseed attenuation in permanent prostate implants. , 2008, Medical physics.

[10]  A. Thilander,et al.  The impact of anatomic variations on absorbed radiation doses in mammography , 1993 .

[11]  J. R. Laeter Atomic Weights of the Elements 1987 , 1988 .

[12]  K. Weaver Anisotropy functions for 125I and 103Pd sources. , 1998, Medical physics.

[13]  S. Chiu‐Tsao,et al.  The use of new GAFCHROMIC® EBT film for I125 seed dosimetry in Solid Water® phantom. , 2008, Medical physics.

[14]  Zuofeng Li,et al.  Monte Carlo and experimental dosimetry of an I125 brachytherapy seed. , 2006, Medical physics.

[15]  E. Rakovitch,et al.  A permanent breast seed implant as partial breast radiation therapy for early-stage patients: a comparison of palladium-103 and iodine-125 isotopes based on radiation safety considerations. , 2005, International journal of radiation oncology, biology, physics.

[16]  L. Anderson,et al.  Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43 , 1995 .

[17]  Frank Verhaegen,et al.  Postimplant dosimetry using a Monte Carlo dose calculation engine: a new clinical standard. , 2007, International journal of radiation oncology, biology, physics.

[18]  C. Ling,et al.  Physical dosimetry of 125I seeds of a new design for interstitial implant. , 1983, International journal of radiation oncology, biology, physics.

[19]  P. Scalliet,et al.  Dosimetric study of the new Intersource125 iodine seed. , 2001, Medical physics.

[20]  Frank Verhaegen,et al.  Tissue segmentation in Monte Carlo treatment planning: a simulation study using dual-energy CT images. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[21]  J. F. Briesmeister MCNP-A General Monte Carlo N-Particle Transport Code , 1993 .

[22]  Harry Easton,et al.  First report of a permanent breast 103Pd seed implant as adjuvant radiation treatment for early-stage breast cancer. , 2006, International journal of radiation oncology, biology, physics.

[23]  K. Weaver Response of LiF powder to 125I photons. , 1984, Medical physics.

[24]  A. Meigooni,et al.  Determination of the dosimetric characteristics of InterSource125 iodine brachytherapy source. , 2002, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[25]  R. Taylor,et al.  Benchmarking brachydose: Voxel based EGSnrc Monte Carlo calculations of TG-43 dosimetry parameters. , 2007, Medical physics.

[26]  F. Verhaegen,et al.  Dual-energy CT-based material extraction for tissue segmentation in Monte Carlo dose calculations , 2008, Physics in medicine and biology.

[27]  C Ross Schmidtlein,et al.  Precise radiochromic film dosimetry using a flat-bed document scanner. , 2005, Medical physics.

[28]  E. Rakovitch,et al.  Tolerance and acceptance results of a palladium-103 permanent breast seed implant Phase I/II study. , 2009, International journal of radiation oncology, biology, physics.

[29]  F Verhaegen,et al.  BrachyGUI: an adjunct to an accelerated Monte Carlo photon transport code for patient-specific brachytherapy dose calculations and analysis , 2008 .

[30]  Omar Chibani,et al.  Dosimetric effects of seed anisotropy and interseed attenuation for Pd103 and I125 prostate implants. , 2005, Medical physics.